Pharmafile Logo
Pharmafocus logo
Advanced Search

GW Pharmaceuticals

Showing 10 posts of 10 posts found.

epilepsy-623346_960_720

Cannabidiol drug found to aid in devastating childhood epilepsy condition

May 25, 2017
Research and Development GW Pharmaceuticals, cannabidoil, epilepsy

A treatment derived from cannabis has been found to produce remarkable results in children who have epilepsy. Cannabidoil, when offered …

News
laboratory

GW Pharma releases positive data on cannabidiol-based Phase III trial

September 28, 2016
Research and Development Epidiolex, GW Pharmaceuticals, Marijuana, Medical marijuana, cannabis

GW Pharmaceuticals’ Epidiolex is designed to treat seizures in a rare form of epilepsy called Lennox-Gaustaut Syndrome. GW pharmaceuticals published …

News
stocks1

Weekly Movers: CytRx, Coherus BioSciences, Juno Therapeutics…

July 15, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Coherus BioSciences, GW Pharmaceuticals, Sage Therapeutics, Share price, Shares, Stock Markets, cytrx, juno therapeutics

Shares in CytRx (Nasdaq: CYTR) lost nearly three-fourth in value after the company reported disappointing late-stage results for its lead …

Feature
gwpharma

GW Pharmaceuticals says Phase III trials for Epidiolex to treat rare epilepsy in children shows positive results

June 27, 2016
Research and Development, Sales and Marketing Epidiolex, GW Pharmaceuticals, NDA, US FDA, drug trial, orphan drug

GW Pharmaceuticals (Nasdaq: GWPH) said late-stage trials for its Epidiolex (cannabidiol or CBD) to treat Lennox-Gastaut syndrome (LGS), a rare …

News
gwpharma

GW Pharma starts Phase III trials for Tuberous Sclerosis Complex drug

April 11, 2016
Research and Development Epidiolex, GW Pharmaceuticals, Tuberous Sclerosis Complex, genetics, rare disease

GW Pharmaceuticals Plc (Nasdaq: GWPH) said it has started late-stage trials for its Epidiolex (cannabidiol or CBD) to treat seizures …

News
julian_gangolli

GW Pharma appoints president and moves CEO to US

May 22, 2015
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GW Pharmaceuticals, Julian Gangolli

US biopharma firm GW Pharmaceuticals has appointed Julian Gangolli as president of its North American division, and is also relocating its …

Appointment
114053815_tovey_341562c

GW Pharmaceuticals hires chief operating officer

October 4, 2012
Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Chris Tovey, GW Pharmaceuticals

GW Pharmaceuticals has announced the appointment of Christopher John Tovey to the newly created position of chief operating officer. Tovey, …

Appointment
GW laboratory

Bayer launches world’s first cannabis-derived prescription drug

June 21, 2010
Sales and Marketing Bayer, GW Pharmaceuticals, Sativex

Bayer Healthcare has launched the world’s first cannabis-derived prescription drug in the UK. Sativex treats the spasticity symptoms of multiple …

News

Cannabis-derived MS treatment filed in Europe

September 5, 2006
Sales and Marketing GW Pharmaceuticals, Sativex

Sativex, the cannabis-derived product developed by GW Pharmaceuticals could be finally set for approval after a delay of around two …

News

Patient demand brings Sativex to UK ahead of approval

November 17, 2005
Sales and Marketing GW Pharmaceuticals, Sativex

The unlicensed cannabis-based medicine Sativex will be available in the UK to treat neuropathic pain on a named patient basis …

News

Latest content

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024